Yen-Yi Chen1, Pei-Ying Chen1,2, Fang-Ting Chen1,3, Yun-Ju Chen1,3, Jia-Kang Wang4,5,6,7,8. 1. Department of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sect. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei, 220, Taiwan. 2. Department of Medicine, Fu Jen Catholic University, New Taipei, Taiwan. 3. Department of Medicine, National Taiwan University, Taipei, Taiwan. 4. Department of Ophthalmology, Far Eastern Memorial Hospital, No. 21, Sect. 2, Nan-Ya South Road, Pan-Chiao District, New Taipei, 220, Taiwan. jiakangw2158@gmail.com. 5. Department of Medicine, National Taiwan University, Taipei, Taiwan. jiakangw2158@gmail.com. 6. Department of Medicine, National Yang Ming University, Taipei, Taiwan. jiakangw2158@gmail.com. 7. Department of Electrical Engineering, Yuan Ze University, Taoyuan, Taiwan. jiakangw2158@gmail.com. 8. Department of Healthcare Administration and Department of Nursing, Oriental Institute of Technology, New Taipei City, Taiwan. jiakangw2158@gmail.com.
Abstract
PURPOSE: To compare the efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema (DME). STUDY DESIGN: A retrospective, nonrandomized, and comparative study. METHODS: From May 2013 to March 2016, 148 eyes of 148 patients with treatment-naïve center-involving DME were reviewed in one institution. Forty-six eyes underwent prior vitrectomy at least 3 months ago, and 102 eyes did not receive any vitrectomy. Three monthly then PRN intravitreal ranibizumab treatments were performed in all the patients with monthly follow-up for 6 months. Primary outcome measures included change in central foveal thickness (CFT) and best-corrected visual acuity (BCVA) at month 6. RESULTS: The CFT significantly reduced, and the BCVA significantly improved 6 months after ranibizumab injections in either vitrectomized or non-vitrectomized groups (p < 0.05). There was no difference between vitrectomized and non-vitrectomized eyes in baseline characteristics. Significantly better final BCVA and visual gain were found in non-vitrectomized eyes than in vitrectomized eyes (p = 0.01 and 0.03, respectively). Final CFT and CFT decrease were significantly greater in non-vitrectomized group than in vitrectomized group (p = 0.02 and 0.006, respectively). Injection number of ranibizumab was 4.12 ± 0.58 in non-vitrectomized eyes, significantly less than that in vitrectomized eyes (5.05 ± 0.71) during 6-month period (p < 0.001). There were no severe systemic/ocular adverse effects in both groups. CONCLUSIONS: Intravitreal ranibizumab was helpful for either vitrectomized or non-vitrectomized eyes with DME in short-term follow-up. Anatomical and functional improvements were greater in non-vitrectomized patients than in vitrectomized cases.
PURPOSE: To compare the efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema (DME). STUDY DESIGN: A retrospective, nonrandomized, and comparative study. METHODS: From May 2013 to March 2016, 148 eyes of 148 patients with treatment-naïve center-involving DME were reviewed in one institution. Forty-six eyes underwent prior vitrectomy at least 3 months ago, and 102 eyes did not receive any vitrectomy. Three monthly then PRN intravitreal ranibizumab treatments were performed in all the patients with monthly follow-up for 6 months. Primary outcome measures included change in central foveal thickness (CFT) and best-corrected visual acuity (BCVA) at month 6. RESULTS: The CFT significantly reduced, and the BCVA significantly improved 6 months after ranibizumab injections in either vitrectomized or non-vitrectomized groups (p < 0.05). There was no difference between vitrectomized and non-vitrectomized eyes in baseline characteristics. Significantly better final BCVA and visual gain were found in non-vitrectomized eyes than in vitrectomized eyes (p = 0.01 and 0.03, respectively). Final CFT and CFT decrease were significantly greater in non-vitrectomized group than in vitrectomized group (p = 0.02 and 0.006, respectively). Injection number of ranibizumab was 4.12 ± 0.58 in non-vitrectomized eyes, significantly less than that in vitrectomized eyes (5.05 ± 0.71) during 6-month period (p < 0.001). There were no severe systemic/ocular adverse effects in both groups. CONCLUSIONS: Intravitreal ranibizumab was helpful for either vitrectomized or non-vitrectomized eyes with DME in short-term follow-up. Anatomical and functional improvements were greater in non-vitrectomized patients than in vitrectomized cases.
Authors: Susan B Bressler; Michele Melia; Adam R Glassman; Talat Almukhtar; Lee M Jampol; Michel Shami; Brian B Berger; Neil M Bressler Journal: Retina Date: 2015-12 Impact factor: 4.256
Authors: Ranjan Rajendram; Samantha Fraser-Bell; Andrew Kaines; Michel Michaelides; Robin D Hamilton; Simona Degli Esposti; Tunde Peto; Catherine Egan; Catey Bunce; Richard David Leslie; Philip G Hykin Journal: Arch Ophthalmol Date: 2012-08
Authors: John B Christoforidis; Michelle M Williams; Jillian Wang; Angela Jiang; Cedric Pratt; Mahmoud Abdel-Rasoul; George H Hinkle; Michael V Knopp Journal: Retina Date: 2013-05 Impact factor: 4.256
Authors: Susan B Bressler; Adam R Glassman; Talat Almukhtar; Neil M Bressler; Frederick L Ferris; Joseph M Googe; Shailesh K Gupta; Lee M Jampol; Michele Melia; John A Wells Journal: Am J Ophthalmol Date: 2016-01-21 Impact factor: 5.258
Authors: Timothy L Jackson; Cristina Soare; Caroline Petrarca; Andrew Simpson; James E Neffendorf; Robert Petrarca; Alyson Muldrew; Tunde Peto; Usha Chakravarthy; Luke Membrey; Richard Haynes; Mark Costen; David Steel; Riti Desai Journal: JAMA Ophthalmol Date: 2020-08-01 Impact factor: 7.389
Authors: Solange Milazzo; Thi Ha Chau Tran; Stephane Verdun; Jean François Le Rouic; Joel Uzzan; Laurent Kodjikian; Ali Erginay Journal: Clin Ophthalmol Date: 2022-03-07
Authors: Hüseyin Baran Özdemir; Murat Hasanreisoğlu; Murat Yüksel; Mestan Ertop; Gökhan Gürelik; Şengül Özdek Journal: Turk J Ophthalmol Date: 2019-12-31